Abdullah Sulieman Terkawi, MD
Anesthesiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Terkawi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A169977 · Current
Licensed to practise in California · since 2020 · expires 2028-08-31 · Sana'A University Faculty of Medicine and Health Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$84,621
Medicare paid this office $84,621 for 303 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 121 | $19,382 | $114 |
| New patient visit (60+ min) | 76 | $15,087 | $199 |
| Long return visit (40+ min) | 56 | $10,407 | $163 |
| New patient visit (45+ min) | 22 | $3,310 | $150 |
| Injection of trigger points, 3 or more muscles | 24 | $2,071 | $58 |
See all 13 services
| Return visit (30+ min) | 121 | $19,382 | $114 |
| New patient visit (60+ min) | 76 | $15,087 | $199 |
| Long return visit (40+ min) | 56 | $10,407 | $163 |
| New patient visit (45+ min) | 22 | $3,310 | $150 |
| Injection of trigger points, 3 or more muscles | 24 | $2,071 | $58 |
| Short return visit (20+ min) | 21 | $2,032 | $81 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 18 | $1,965 | $103 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 20 | $1,360 | $65 |
| Injection of substance into lower spine canal using imaging guidance | 16 | $1,350 | $79 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 17 | $1,021 | $57 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $293 | $10 |
| Injection, ropivacaine hydrochloride, 1 mg | 57 | $208 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 34 | $107 | None |
Who their Medicare patients are
303 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 11% · Women 66% · Also on Medicaid 26% · Health risk score 1.52. At or below the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 74% · Depression 32% · Diabetes 28% · Coronary heart disease 28% · Chronic kidney disease 20% · Cancer 18% · Heart failure 17% · Atrial fibrillation 17% · COPD 10% · Stroke 9% · Dementia 6%.
The office billed $1,158,877, Medicare allowed $109,229 and paid $84,621; for 6,699 services of 55 kinds; $8,231 of it was for drugs given in the office and $76,390 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 303 | 6,699 | 73 | 1.52 | $1,158,877 | $84,621 |
| 2023 | 297 | 3,216 | 72 | 1.51 | $739,475 | $64,570 |
| 2022 | 310 | 635 | 70 | 1.60 | $874,033 | $60,277 |
| 2021 | 127 | 275 | 70 | 1.55 | $260,781 | $22,656 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 96 | $13,828 | $107 |
| Long return visit (40+ min) | 66 | $11,587 | $145 |
| New patient visit (60+ min) | 64 | $11,332 | $177 |
| Telehealth originating site facility fee | 61 | $1,818 | $22 |
| New patient visit (45+ min) | 14 | $1,794 | $128 |
| Injection of trigger points, 3 or more muscles | 31 | $1,678 | $44 |
| Short return visit (20+ min) | 23 | $1,488 | $62 |
| Aspiration and/or injection of fluid from large joint | 19 | $970 | $49 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 17 | $828 | $49 |
| Injection of trigger points, 1-2 muscles | 11 | $419 | $38 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 43 | $203 | $5 |
| Injection, ropivacaine hydrochloride, 1 mg | 31 | $116 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $66 | None |
2022: 13 services
| Long return visit (40+ min) | 92 | $16,889 | $137 |
| New patient visit (60+ min) | 86 | $15,005 | $174 |
| Return visit (30+ min) | 55 | $5,409 | $93 |
| Injection of substance into lower spine canal using imaging guidance | 18 | $1,447 | $80 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,133 | $94 |
| Injection of trigger points, 3 or more muscles | 20 | $731 | $33 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 11 | $676 | $56 |
| Telehealth originating site facility fee | 26 | $666 | $21 |
| Ultrasonic guidance for needle placement | 17 | $518 | $26 |
| Aspiration and/or injection of fluid from large joint | 12 | $500 | $42 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 13 | $416 | $32 |
| Injection of trigger points, 1-2 muscles | 13 | $404 | $31 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 58 | $300 | $5 |
2021: 5 services
| Long return visit (40+ min) | 36 | $5,605 | $133 |
| Return visit (30+ min) | 41 | $4,240 | $90 |
| New patient visit (60+ min) | 24 | $4,037 | $168 |
| Ultrasonic guidance for needle placement | 32 | $1,053 | $28 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $62 | $5 |
Medicaid work
$350 in 2024
Medicaid paid $350 for 13 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 13 | $350 |
| 2024 | 13 | 1 | 12 | $350 |
| 2023 | 40 | 2 | 15 | $863 |
| 2021 | 24 | 2 | 12 | $423 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 25 | $692 |
| Telehealth originating site facility fee | 15 | $171 |
2021
| Return visit (30+ min) | 12 | $281 |
| Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | 12 | $143 |
Drugs they prescribed that Part D paid
$5,651
Pharmacies billed $5,651 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 12% of their Part D prescriptions (11 of 96) in 2024. Above the middle of the specialty; the typical anesthesiology clinician is at 0%.
91 generic and fewer than 11 brand-name prescriptions · $5,651 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Duloxetine | 28 | $801 | $29 |
| Pregabalin | 14 | $254 | $18 |
Year by year
| 2024 | 96 | 48 | 12% (11) | None | $5,651 |
| 2023 | 86 | 40 | None | None | $10,509 |
| 2022 | 136 | 55 | 10% (13) | None | $3,789 |
| 2021 | 131 | 39 | None | None | $3,596 |
| 2020 | 18 | 14 | 0% (0) | 0% | $348 |
| 2018 | 16 | None | None | None | $1,550 |
| 2016 | 20 | 11 | None | None | $964 |
| 2015 | 19 | 13 | None | None | $978 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Duloxetine | 23 | $746 | $32 |
| Celecoxib | 17 | $346 | $20 |
| Gabapentin | 16 | $159 | $10 |
2022: 4 drugs
| Pregabalin | 21 | $876 | $42 |
| Celecoxib | 24 | $724 | $30 |
| Gabapentin | 25 | $558 | $22 |
| Duloxetine | 23 | $535 | $23 |
2021: 4 drugs
| Pregabalin | 18 | $1,356 | $75 |
| Celecoxib | 36 | $784 | $22 |
| Gabapentin | 40 | $557 | $14 |
| Duloxetine | 21 | $458 | $22 |
Money from drug and device companies
$51 in 2025
| 2025 | 1 | 1 | None | $51 |
| 2024 | 6 | 22 | None | $4,957 |
| 2023 | 1 | 1 | None | $242 |
| 2022 | 5 | 14 | None | $1,433 |
| 2021 | 4 | 9 | None | $544 |
| 2020 | 2 | 6 | None | $160 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Curonix | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A | $51 | 1 payment
|
See the published payment
| Curonix | Meals · 2025-10-07 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A | $51 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $4,957
| Abbott Laboratories | Proclaim | $3,325 | 9 payments
|
| Spinal Simplicity | Ha Minuteman G3-R | $846 | 2 payments
|
| Medtronic | Kyphon Express II Kyphopak Tray | $379 | 6 payments
|
| Biotronik Nro | Prospera | $225 | 3 payments
|
| Painteq | Painteq | $115 | 1 payment
|
| Curonix | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A | $67 | 1 payment
|
2023: $242
| Painteq | Painteq | $242 | 1 payment
|
2022: $1,433
| Vertos Medical | Mild Device Kit | $1,073 | 5 payments
|
| Nevro | Omnia | $146 | 2 payments
|
| Abbott Laboratories | Proclaim | $108 | 3 payments
|
| SPR Therapeutics | Sprint Pns System | $86 | 1 payment
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W/Receiver | $20 | 3 payments
|
2021: $544
| Abbott Laboratories | Proclaim Ipg | $244 | 6 payments
|
| Nevro | Omnia | $152 | 1 payment
|
| SPR Therapeutics | Sprint Pns System | $86 | 1 payment
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W Receiver | $62 | 1 payment
|
2020: $160
| Medtronic USA | Restore | $84 | 3 payments
|
| Boston Scientific | Spectra Wavewriter | $76 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285044511
- Licence
- CA A169977California A169977: Current · expires 2028-08-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-05-08
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1215 Lee St, Charlottesville, VA, 22908